US 12,110,292 B2
Ligands to cereblon (CRBN)
Nathanael Gray, Stanford, CA (US); Tinghu Zhang, Brookline, MA (US); Eric Fischer, Chestnut Hill, MA (US); Zhixiang He, Brookline, MA (US); Guangyan Du, Jamaica Plain, MA (US); Katherine Donovan, Boston, MA (US); Radoslaw Nowak, Boston, MA (US); and Jing Ting Christine Yuan, Baltimore, MD (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed on Nov. 11, 2022, as Appl. No. 17/985,415.
Application 17/985,415 is a continuation of application No. 17/255,734, granted, now 11,530,219, previously published as PCT/US2019/039555, filed on Jun. 27, 2019.
Claims priority of provisional application 62/692,167, filed on Jun. 29, 2018.
Prior Publication US 2023/0312575 A1, Oct. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 405/14 (2006.01); A61P 35/00 (2006.01); C07D 473/16 (2006.01); C07D 473/34 (2006.01)
CPC C07D 473/16 (2013.01) [A61P 35/00 (2018.01); C07D 405/14 (2013.01); C07D 473/34 (2013.01)] 16 Claims
 
1. A compound of Formula (Ia1) or Formula (Ib1):

OG Complex Work Unit Chemistry
wherein:
Z represents CH2;
R2 is H or C1-C2 alkyl; and
R3 is optionally substituted C1-C5 alkyl, optionally substituted C6-C14 aryl, optionally substituted C6-C14 heteroaryl, optionally substituted C5-C14 carbocyclic or optionally substituted C5-C14 heterocyclic, or R2 and R3 together with the N to which they are bound form an optionally substituted C6-C14 heterocyclic group or an optionally substituted C6-C14 heteroaryl group;
or a pharmaceutically acceptable salt or stereoisomer thereof.